Cystic Fibrosis (CF) Therapeutics Market Analysis By Drug Class (Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, CFTR Modulators), By Route of Administration, By Region, And Segment Forecasts, 2014 - 2025

Published: Jun, 2017 | Pages: 80 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global cystic fibrosis therapeutics market is expected to reach USD 13.9 billion by 2025, according to a new report by Grand View Research, Inc. The rising prevalence of Cystic Fibrosis (CF) globally, research & development activities undertaken by key players, and favorable initiatives undertaken by nonprofit organizations are expected to boost the market over the forecast period.

The rising prevalence of CF indicates the rising demand for treatment alternatives, thereby uplifting the market. The key players operating in this market in collaboration with nonprofit organizations focus on the development of novel therapeutics for treatment. Some of the drugs that are under clinical studies are VX-445 + tezacaftor + ivacaftor, PTI-428, QR-010, AZD5634, and POL6014.

Favorable initiatives taken by regional and national nonprofit organizations is one of the key factors propelling growth. These initiatives ensure support to CF patients. These organizations aid in research & development activities of these therapeutics and help improve the quality of life of these patients. For instance, North American Cystic Fibrosis Conference (NACFC) was formed in 1986 to provide a collaborative and educational forum to CF professionals to share advances in R&D related to CF therapeutics.

Further key findings from the report suggest:

• The global CF therapeutics market size was estimated at USD 3,560.5 million in 2016 and is expected to grow at a CAGR of 16.7% from 2017 to 2025

• The CFTR modulator segment emerged as the largest segment in 2016 and the same segment is anticipated to witness fastest growth over the next 8 years owing to the approval of CFTR modulator, Orkambi and the presence of various investigational compounds under the pipeline.

• Oral route of administration emerged as the largest segment with revenue of USD 2,266.4 million due to the ease of administration and convenience

• North America accounted for the largest market share owing to the presence of Caucasian descents in this region. Improved healthcare infrastructure, reimbursements, and initiatives undertaken by the nonprofit organizations is expected to propel the market over forecast period,

• The key players include AbbVie Inc., F. Hoffmann-La Roche Ltd.; Gilead, Novartis AG, Vertex Pharmaceuticals Inc., AIT (Advanced Inhalation Therapies), Alaxia, Teva Pharmaceutical Industries Ltd, Merck & Co. Inc., Alcresta Therapeutics Inc., Allergan, and AstraZeneca

 Table of Contents

Chapter 1. Methodology and Scope
                 1.1. Research Methodology
                 1.2. Research Scope & Assumptions
                 1.3. List of Data Sources
Chapter 2. Executive Summary
                 2.1. Market Snapshot
Chapter 3. Cystic Fibrosis Therapeutics Market Variables, Trends & Scope
                 3.1. Market Segmentation
                 3.2. Market Dynamics
                     3.2.1. Market driver analysis
                     3.2.2. Market restraint analysis
                 3.3. Key Opportunities Prioritized
                 3.4. Industry Analysis - Porter's
                 3.5. Cystic Fibrosis Therapeutics Market-SWOT Analysis, By Factor (Political & Legal, Economic and Technological), 2015
Chapter 4. Cystic Fibrosis Therapeutics Market: Drug Class Estimates & Trend Analysis
                 4.1. Cystic Fibrosis Therapeutics Market Share by Drug Class, 2016 & 2025 (USD Million)
                 4.2. Pancreatic Enzyme Supplements
                     4.2.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                 4.3. Mucolytics
                     4.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                 4.4. Bronchodilators
                     4.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                 4.5. CFTR Modulators
                     4.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
Chapter 5. Cystic Fibrosis Therapeutics Market: Route of Administration Estimates & Trend Analysis
                 5.1. Cystic Fibrosis Therapeutics Market Share by Route of Administration, 2016 & 2025 (USD Million)
                 5.2. Oral Drugs
                     5.2.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                 5.3. Inhaled Drugs
                     5.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
Chapter 6. Cystic Fibrosis Therapeutics Market: Regional Outlook, by Drug Class and Route of Administration
                 6.1. Cystic Fibrosis Therapeutics Market Shares by Region, 2016 & 2025 (USD Million)
                 6.2. North America
                     6.2.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                     6.2.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                     6.2.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                     6.2.4. U.S.
                         6.2.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                         6.2.4.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                         6.2.4.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                     6.2.5. Canada
                         6.2.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                         6.2.5.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                         6.2.5.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                 6.3. Europe
                     6.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                     6.3.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                     6.3.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                     6.3.4. Germany
                         6.3.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                         6.3.4.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                         6.3.4.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                     6.3.5. UK
                         6.3.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                         6.3.5.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                         6.3.5.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                 6.4. Asia Pacific
                     6.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                     6.4.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                     6.4.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                     6.4.4. China
                         6.4.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                         6.4.4.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                         6.4.4.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                     6.4.5. Japan
                         6.4.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                         6.4.5.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                         6.4.5.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                 6.5. Latin America
                     6.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                     6.5.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                     6.5.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                     6.5.4. Brazil
                         6.5.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                         6.5.4.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                         6.5.4.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                     6.5.5. Mexico
                         6.5.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                         6.5.5.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                         6.5.5.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                 6.6. Middle East & Africa 
                     6.6.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                     6.6.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                     6.6.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
                     6.6.4. South Africa
                         6.6.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
                         6.6.4.2. Market estimates and forecast by drug class, 2014 - 2025 (USD Million)
                         6.6.4.3. Market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
Chapter 7. Competitive Landscape
                 7.1. Strategic Framework
                 7.2. Company Profiles
                     7.2.1. AbbVie Inc.
                         7.2.1.1. Company overview
                         7.2.1.2. Financial performance
                         7.2.1.3. Product benchmarking
                         7.2.1.4. Strategic initiatives
                     7.2.2. F. Hoffmann-La Roche Ltd
                         7.2.2.1. Company overview
                         7.2.2.2. Financial performance
                         7.2.2.3. Product benchmarking 
                         7.2.2.4. Strategic initiatives
                     7.2.3. Gilead
                         7.2.3.1. Company overview
                         7.2.3.2. Financial performance
                         7.2.3.3. Product benchmarking
                         7.2.3.4. Strategic initiatives
                     7.2.4. Novartis AG
                         7.2.4.1. Company overview
                         7.2.4.2. Financial performance
                         7.2.4.3. Product benchmarking 
                         7.2.4.4. Strategic initiatives
                     7.2.5. Vertex Pharmaceuticals Incorporated
                         7.2.5.1. Company overview
                         7.2.5.2. Financial performance
                         7.2.5.3. Product benchmarking 
                         7.2.5.4. Strategic initiatives
                     7.2.6. AIT (Advanced Inhalation Therapies)
                         7.2.6.1. Company overview
                         7.2.6.2. Financial performance
                         7.2.6.3. Product benchmarking
                         7.2.6.4. Strategic initiatives
                     7.2.7. Alaxia 
                         7.2.7.1. Company overview
                         7.2.7.2. Financial performance
                         7.2.7.3. Product benchmarking 
                         7.2.7.4. Strategic initiatives
                     7.2.8. Teva Pharmaceutical Industries Ltd.
                         7.2.8.1. Company overview
                         7.2.8.2. Financial performance
                         7.2.8.3. Product benchmarking
                         7.2.8.4. Strategic initiatives
                     7.2.9. Merck & Co. Inc.
                         7.2.9.1. Company overview
                         7.2.9.2. Financial performance
                         7.2.9.3. Product benchmarking 
                         7.2.9.4. Strategic initiatives
                     7.2.10. Alcresta Therapeutics, Inc.
                         7.2.10.1. Company overview
                         7.2.10.2. Financial performance
                         7.2.10.3. Product benchmarking 
                         7.2.10.4. Strategic initiatives
                     7.2.11. ALLERGAN
                         7.2.11.1. Company overview
                         7.2.11.2. Financial performance
                         7.2.11.3. Product benchmarking 
                         7.2.11.4. Strategic initiatives
                     7.2.12. AstraZeneca
                         7.2.12.1. Company overview
                         7.2.12.2. Financial performance
                         7.2.12.3. Product benchmarking 
                         7.2.12.4. Strategic initiatives

List of Tables

TABLE 1 North America cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 2 North America cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 3 U.S. cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 4 U.S. cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 5 Canada cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 6 Canada cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 7 Europe cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 8 Europe cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 9 Germany cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 10 Germany cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 11 UK cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 12 UK cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 13 Asia Pacific cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 14 Asia Pacific cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 15 China cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 16 China cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 17 Japan cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 18 Japan cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 19 Latin America cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 20 Latin America cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 21 Mexico cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 22 Mexico cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 23 Brazil cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 24 Brazil cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 25 Middle East and Africa cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 26 Middle East and Africa cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)
TABLE 27 South Africa cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 - 2025 (USD Million)
TABLE 28 South Africa cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 - 2025 (USD Million)